Compugen reported Q4 FY 2025 revenue of USD 67.3 million (up from USD 1.5 million) and FY 2025 revenue of USD 72.8 million (up from USD 27.9 million), reflecting a USD 65 million upfront payment from AstraZeneca tied to monetization of a small portion of royalties on rilvegostomig, as well as amounts related to its Gilead license agreement. Q4 net income was USD 56.8 million, and FY net income was USD 35.3 million; cash and equivalents and related balances totaled USD 145.6 million at Dec. 31, 2025, with no debt and expected cash runway into 2029. R&D expense was USD 5.5 million in Q4 and USD 22.8 million in FY, while G&A expense was USD 2.1 million in Q4 and USD 8.9 million in FY. The company said the AstraZeneca deal also adds USD 25 million to the next potential milestone payment upon BLA acceptance, while Compugen retains the majority of future royalties and remains eligible for tiered royalties up to mid-single digits and potential future regulatory and commercial milestones of up to USD 195 million (including the USD 25 million). Compugen highlighted leadership changes including the appointment of Eran Ophir as CEO and Anat Cohen-Dayag’s transition to executive chair, initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead-partnered GS-0321, and said it remains on track for a MAIA-ovarian interim analysis in Q1 2027. AstraZeneca reported Phase 2 rilvegostomig data at ESMO 2025 and has 10 ongoing Phase 3 trials, with additional Phase 1/2 data anticipated in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000661), on March 02, 2026, and is solely responsible for the information contained therein.